Positioning no disclosures inside 60 days, left as found
Options put/call open interest 0.86, read 2026-11-08
Ethical does not pass the values gate
Price116.70 USD
Fair value89.29
Ethical score70.0/100
Value readOvervaluedas of 6 Nov 2026
Our investment reviews on this name
2026-11-05Read Markdown117.49-0.7% to today ✓Markup gives way to Markdown after an 11% rise in 5 weeks
2026-10-02Read Markup106.15+9.9% to today ✓Markdown gives way to Markup first Markup read since July
2026-08-14Read Markdown102.10+14.3% to today Markup gives way to Markdown after a 26% slide in 6 weeks
2026-07-02Read Markup138.44-15.7% to today First review on file: Markup
Our analytic regime reads on this name, dated and marked against the screened price. Small sample per name, and separate from the daily-framework accuracy on the Track Record page.
Synaptics Incorporated holds its Markdown at $116.70. The statistical read favours the buyers, held for 5 days.
As held on the ledger · 2026-11-06
Phase
Markdown · caution
Quantitative state
The statistical read favours the buyers, held for 5 days
Price at the screen
$116.70
Valuation
N/A trailing · 17.86 forward price to earnings
Values screen
FAIL· score 70.0
Beta
2.02
The Workings
Five Screens, Shown in Full
Does not pass. Debt ratio
Test
Figure
Limit
What it means
Status
Business activity
Permissible
Core business clean
Its core business isn't built on prohibited lines: no gambling, alcohol, tobacco, weapons, or interest-based lending.
Pass
Debt load
34.06%
Below 33%
Interest-bearing debt is 34.1% of its assets, above the one-third ceiling the screen allows.
Fail
Interest-bearing cash
2.36%
Below 33%
Cash held in interest-bearing accounts and securities is 2.4% of assets, under the one-third limit.
Pass
Receivables
20.19%
Below 49%
Money owed to the company is 20.2% of assets, under the 49% limit.
Pass
Revenue purity
2.50%
Below 5%
Only 2.5% of revenue comes from non-compliant sources, under the 5% line.
Pass
Five checks adapted from AAOIFI screening standards: business activity plus four balance-sheet ratios. All five must pass for ethical clearance. Every figure is arithmetic on public accounts, not judgement.
The Ethical Read
Why It Falls Short, in Plain English
Synaptics's business is in a permissible area, but its interest-bearing debt is about 34% of the company, just over the ~33% line, so it does not pass on the financial screens.
Read as at 2026-11-08. It updates when the underlying figures move, and past reads are kept below.
Follow this verdict
Get an email when SYNA's ethical verdict changes
Today SYNA does not pass the screen. If new figures move it to a pass, we send you one short email with the before and after. Verdicts change rarely, so you may not hear from us for a long time.
Free, no account needed. Every email has a link to stop.
What the Numbers Say It Is Worth
The Fair Value Range
Our analysis reads Overvalued vs our fair value, as of 6 Nov 2026: it trades above our $89.29 fair value estimate, 8.90% revenue growth.
Fair value range in USD, drawn from the 2026-11-06 screen. The gold marker is the market price at the same screen. The price runs 30.7% above the base estimate.
Third-party analyst targets: 9 covering, consensus Hold. The average target sits +5% from the screen price.
Reading the gap · Our more conservative model reads it as fully-to-richly valued here, while the Street is more bullish: a quality-at-a-fair-price name rather than a deep-value one.
Where our models see it going: fair-value estimate $89.29, with a range of $89.29 to $102.68, dated to the 2026-11-06 screen.
Fair value and rating are our own model estimates; the Street's range reflects third-party analyst estimates. Analysis, not advice.
The Business, in Plain Words
Touch Chips Lose Money in a Cyclical Trade
Every time a driver taps a car screen or a worker swipes an industrial panel, Synaptics chips sit behind the interaction. Yet the company posted a negative four percent profit margin and negative four percent return on equity last period, even as revenue grew ten percent. At a forward multiple of twenty one point six times earnings and a share price well above our fair value, the business shows no margin of safety.
We pass because this is a classic cyclical semiconductor name trading at an ordinary multiple while still unprofitable. Low returns and unknown competitive edge leave little room for error when demand turns, and peak-cycle earnings often flatten or fall just as multiples compress. The ethical screen clears, yet the financials do not.
Risk sits in the exposure to auto and industrial spending swings that can erase years of modest growth in a single downturn. Nine analysts see a higher target, but that optimism has not translated into current profits. Analysis, not advice.
Another profit measure, before interest, tax and non-cash costs: EBITDA.
The risks · The things to watch: it already moves more than the market on an average day.
Plain-English interpretation of our own screen data. Analysis, not advice.
Where & How to Trade
SYNA trades on Nasdaq. As a listed security it is accessible through almost any international broker offering its home market. New to this, or investing from abroad? Our guide to accessing global markets covers brokers, currencies and the practical steps.
The Dated Journal · Newest First, Never Edited
Every Entry, As Written
2026-11-05Markdown · changed$117.49+0.1%Entry 16
The framework has shifted from markup to markdown since the last review. Price is trending lower. Sellers are in control and the prior trend has reversed. Price has moved up 0.1% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it C. Technically it is holding around 26% above its long-term trend line with momentum reading oversold. Over the past year the shares are up 95%. Our forward projection puts the odds of a 10% gain over the next month near 32%. The street (11 analysts) rates it buy, with a mean price target of $126. Insiders have been net sellers over the past quarter. It reported earnings in this window, a natural checkpoint for the thesis.
2026-11-04Markup$117.41-0.4%Entry 15
The analysis reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved down 0.4% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it C. Technically it is holding around 26% above its long-term trend line with momentum reading oversold. Over the past year the shares are up 95%. Our forward projection puts the odds of a 10% gain over the next month near 32%. The street (11 analysts) rates it buy, with a mean price target of $126. Insiders have been net sellers over the past quarter. It reported earnings in this window, a natural checkpoint for the thesis.
2026-11-03Markup$117.86+0.0%Entry 14
The analysis reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved down 0.0% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it C. Technically it is holding around 26% above its long-term trend line with momentum reading oversold. Over the past year the shares are up 95%. Our forward projection puts the odds of a 10% gain over the next month near 32%. The street (11 analysts) rates it buy, with a mean price target of $126. Insiders have been net sellers over the past quarter. It reported earnings in this window, a natural checkpoint for the thesis.
2026-11-02Markup$117.86+0.0%Entry 13
The analysis reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved down 0.0% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it C. Technically it is holding around 26% above its long-term trend line with momentum reading oversold. Over the past year the shares are up 95%. Our forward projection puts the odds of a 10% gain over the next month near 32%. The street (11 analysts) rates it buy, with a mean price target of $126. Insiders have been net sellers over the past quarter. It reported earnings in this window, a natural checkpoint for the thesis.
2026-11-01Markup$117.86+0.5%Entry 12
The analysis reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved up 0.5% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it B. Technically it is holding around 26% above its long-term trend line with momentum reading oversold. Over the past year the shares are up 95%. Our forward projection puts the odds of a 10% gain over the next month near 32%. The street (11 analysts) rates it buy, with a mean price target of $126. Insiders have been net sellers over the past quarter. It reported earnings in this window, a natural checkpoint for the thesis.
2026-10-31Markup$117.26+0.0%Entry 11
The analysis reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved down 0.0% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it B. Technically it is holding around 26% above its long-term trend line with momentum reading oversold. Over the past year the shares are up 95%. Our forward projection puts the odds of a 10% gain over the next month near 32%. The street (11 analysts) rates it buy, with a mean price target of $126. Insiders have been net sellers over the past quarter. It reported earnings in this window, a natural checkpoint for the thesis.
2026-10-30Markup$117.26+0.0%Entry 10
The analysis reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved down 0.0% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it B. Technically it is holding around 26% above its long-term trend line with momentum reading oversold. Over the past year the shares are up 95%. Our forward projection puts the odds of a 10% gain over the next month near 32%. The street (11 analysts) rates it buy, with a mean price target of $126. Insiders have been net sellers over the past quarter. It reported earnings in this window, a natural checkpoint for the thesis.
2026-10-29Markup$117.26-0.2%Entry 9
The analysis reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved down 0.2% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it B. Technically it is holding around 26% above its long-term trend line with momentum reading oversold. Over the past year the shares are up 95%. Our forward projection puts the odds of a 10% gain over the next month near 32%. The street (11 analysts) rates it buy, with a mean price target of $126. Insiders have been net sellers over the past quarter. It reported earnings in this window, a natural checkpoint for the thesis.
2026-10-23Markup$117.48+0.1%Entry 8
The analysis reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved up 0.1% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it B. Technically it is holding around 28% above its long-term trend line with momentum reading overbought. Over the past year the shares are up 95%. Our forward projection puts the odds of a 10% gain over the next month near 32%. The street (11 analysts) rates it buy, with a mean price target of $126. Insiders have been net sellers over the past quarter.
2026-10-16Markup$117.36+10.6%Entry 7
The analysis reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved up 10.6% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it C. Technically it is holding around 80% above its long-term trend line with momentum reading overbought. Over the past year the shares are up 95%. Our forward projection puts the odds of a 10% gain over the next month near 32%. The street (11 analysts) rates it buy, with a mean price target of $126. Insiders have been net sellers over the past quarter.
Each entry above was written on its date, before the outcome. A journal you can prune is not a journal.
